期刊
COLD SPRING HARBOR PERSPECTIVES IN MEDICINE
卷 11, 期 5, 页码 -出版社
COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
DOI: 10.1101/cshperspect.a040493
关键词
-
资金
- Swiss National Science Foundation [32003B-173092]
- Swiss National Science Foundation (SNF) [32003B_173092] Funding Source: Swiss National Science Foundation (SNF)
The advancement in biotechnology has greatly facilitated the collection of omics data in large sample sizes worldwide. Studies associating diseases with genetic markers have led to biologically meaningful mechanisms, but identifying disease biomarkers may be just correlates of diseases. Mendelian randomization offers a framework to integrate omics and disease-associated genetic variants to pinpoint molecular traits driving disease development.
Major biotechnological advances have facilitated a tremendous boost to the collection of (gen-/transcript-/prote-/methyl-/metabol-)omics data in very large sample sizes worldwide. Coordinated efforts have yielded a deluge of studies associating diseases with genetic markers (genome-wide association studies) or with molecular phenotypes. Whereas omics-disease associations have led to biologically meaningful and coherent mechanisms, the identified (non-germline) disease biomarkers may simply be correlates or consequences of the explored diseases. To move beyond this realm, Mendelian randomization provides a principled framework to integrate information on omics- and disease-associated genetic variants to pinpoint molecular traits causally driving disease development. In this review, we show the latest advances in this field, flag up key challenges for the future, and propose potential solutions.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据